Dr. Hafiz Ahmed Ahmed is an experienced scientist and prior faculty member at the University of Maryland, Baltimore (UMB). He is an expert in protein chemistry, oncology/onco-immunology, and glycobiology, particularly protein-carbohydrate interactions in cancer and metabolic disease. At the UMB, he implemented short and long-term strategic R&D programs which led to the identification of a high-affinity glycopeptide—a promising anti-metastatic agent for the treatment of various cancers, including prostate adenocarcinoma. He founded GlycoMantra, Inc. based on this technology and has continued the discovery and pre-clinical development program on a commercial pathway. He is passionate about this technology and remains the driving force behind the program. Thus far, he successfully led cancer and fibrosis programs that achieved preclinical validation. He participated in the NIH I-CORPS and NCI Investor Initiative programs and the TEDCO Executive Roundtables. Dr. Ahmed has published 90 peer-reviewed original articles in high-impact journals including PNAS and Biomaterials. He authored a book on protein techniques, edited “Glycobiology of Cancer”, and co-edited a book on animal lectins. He is a lead inventor of five US patents and currently serves as an editorial board member of five journals and a reviewer of many reputed journals. He is also serving NIH Study Section. He has served as PI of 13 grants (11 federal and two state) and has, so far, secured $5.6 million as PI/Co-PI.